Sobi to streamline nirsevimab contractual arrangements

Nirsevimab economics simplified through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca Alignment will provide Sobi benefit through simplification, only revenue recognition and greater flexibility STOCKHOLM, April 9, 2023...